 The purpose of this study is to evaluate the safety and immune response of multiple peptides URLC10, TTK, KOC1 VEGFR1, and VEGFR2 emulsified with Montanide ISA51 in combination with chemotherapy CDDP, 5-FU plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer. 